½ÃÀ庸°í¼­
»óǰÄÚµå
1600157

Àúħ½À ³ì³»Àå ¼ö¼ú ±â±â ½ÃÀå : ±â±â, ÀûÀÀÁõ, ¼ö¼ú, ÃÖÁ¾»ç¿ëÀÚº° - ¼¼°è ¿¹Ãø(2025-2030³â)

Minimally Invasive Glaucoma Surgery Devices Market by Device (Micro-Stents, Suprachoroidal Devices, Trabecular Meshwork Devices), Indication (Closed-Angle Glaucoma, Open-Angle Glaucoma), Surgery, End-User - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 194 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Àúħ½À ³ì³»Àå ¼ö¼ú ±â±â ½ÃÀåÀº 2023³â¿¡ 5¾ï 135¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â¿¡´Â 5¾ï 2,662¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 5.35%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 7¾ï 2,255¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Àúħ½À ³ì³»Àå ¼ö¼ú(MIGS) Àåºñ´Â ¾È¾ÐÀ» ³·Ãßµµ·Ï ¼³°èµÇ¾úÀ¸¸ç, ÁÖ·Î °æÁõ¿¡¼­ ÁߵÀÇ ³ì³»Àå ȯÀÚ¿¡°Ô »ç¿ëµË´Ï´Ù. ±âÁ¸ ¼ö¼ú¹ý¿¡ ºñÇØ ´ú ħ½ÀÀûÀ̱⠶§¹®¿¡ ¾È°ú ¼ö¼ú¿¡¼­ ¸Å¿ì Áß¿äÇÑ °³¹ßǰÀÌ µÇ¾úÀ¸¸ç, MIGS ÀåºñÀÇ ¹üÀ§´Â Àü ¼¼°è Àα¸ÀÇ °í·ÉÈ­, ³ì³»Àå À¯º´·ü Áõ°¡, º¸´Ù ¾ÈÀüÇÑ ´ëü Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä·Î ÀÎÇÑ Çʿ伺À» Æ÷°ýÇϰí ÀÖ½À´Ï´Ù. ÀÌ Àåºñ´Â ½ºÅÙÆ®, ¼ÇÆ® µî ´Ù¾çÇÑ ÇüÅ·ΠÀû¿ë °¡´ÉÇϸç, ¾È°ú ÀÇ»çµéÀÌ ´Üµ¶À¸·Î ¶Ç´Â ¹é³»Àå ¼ö¼ú°ú ÇÔ²² Á¤±âÀûÀ¸·Î »ç¿ëÇϰí ÀÖ½À´Ï´Ù. ÃÖÁ¾ »ç¿ëó¿¡´Â Ŭ¸®´Ð, º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)°¡ Æ÷ÇÔµÇÁö¸¸, ¼÷·ÃµÈ Àü¹®°¡¿Í ÷´Ü ÀåºñÀÇ °¡¿ë¼ºÀ¸·Î ÀÎÇØ ÇöÀç º´¿øÀÌ ¿ìÀ§¸¦ Á¡Çϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ[2023] 5¾ï 135¸¸ ´Þ·¯
¿¹Ãø³â[2024] 5¾ï 2,662¸¸ ´Þ·¯
¿¹Ãø³â[2030] 7¾ï 2,255¸¸ ´Þ·¯
CAGR(%) 5.35%

MIGS ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î´Â ³ëÈ­¿¡ µû¸¥ ¾ÈÁúȯ ¹ß»ý·ü Áõ°¡¿Í ³ì³»Àå¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡¸¦ µé ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿Ü·¡ ¼ö¼ú¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ ½ÃÀå È®´ë°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. °³¹ßµµ»ó±¹¿¡¼­ÀÇ Á¢±Ù¼º°ú º¸±ÞÀ» ³ôÀ̱â À§ÇÑ Ã·´ÜÀ̸鼭µµ ºñ¿ë È¿À²ÀûÀÎ Àåºñ °³¹ß¿¡´Â ºñÁî´Ï½º ±âȸ°¡ ÀÖ½À´Ï´Ù. ±â¾÷Àº ±â¼ú ¾÷±×·¹À̵å¿Í »õ·Î¿î ¼ö¼ú¹ý ¸ð»ö¿¡ ÁßÁ¡À» µÐ ¿¬±¸ ¹× Á¦ÈÞ¿¡ ÅõÀÚÇÏ´Â °ÍÀÌ ¹Ù¶÷Á÷ÇÕ´Ï´Ù. ±×·¯³ª MIGS ÀåºñÀÇ °í°¡, ¼ö¼ú ÈÄ ÇÕº´Áõ ¹ß»ý °¡´É¼º, ¼÷·ÃµÈ Àü¹®°¡ÀÇ ¼ö°¡ Á¦ÇÑÀûÀ̶ó´Â Á¡ µîÀ¸·Î ÀÎÇØ ½ÃÀåÀº ÇѰ迡 Á÷¸éÇØ ÀÖ½À´Ï´Ù.

¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°Ç°ú ƯÁ¤ Áö¿ª¿¡¼­ÀÇ »óȯ Á¤Ã¥ÀÇ ºÎÀçµµ ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. Çõ½ÅÀ» ÃËÁøÇϱâ À§ÇØ ±â¾÷Àº Â÷¼¼´ë »ýüÀûÇÕ¼º ¼ÒÀç °³¹ß°ú ±â±â »ç¿ë ÆíÀǼº Çâ»ó¿¡ ÁýÁßÇØ¾ß Çϸç, À̸¦ ÅëÇØ Àû¿ë ¹üÀ§°¡ ´õ¿í È®´ëµÉ ¼ö ÀÖ½À´Ï´Ù. ȯÀÚ ¸ÂÃãÇü Ä¡·á ¿É¼Ç°ú °³ÀÎ ¸ÂÃãÇü Ä¡·á ¸ðµ¨¿¡ ´ëÇÑ ¿¬±¸´Â »ç¾÷ ¼ºÀåÀ» À§ÇÑ ±ÍÁßÇÑ °³Ã´ÁöÀ̸ç, MIGS ½ÃÀåÀº ¿Ï¸¸ÇÑ °æÀïÀÌ Æ¯Â¡À̸ç, ÁÖ¿ä ¾÷üµéÀº °æÀï ¿ìÀ§¸¦ À¯ÁöÇϱâ À§ÇØ ¿¬±¸°³¹ß¿¡ ÁýÁßÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ÃÖ¼Òħ½À ³ì³»Àå ¼ö¼ú Àåºñ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

Àúħ½À ³ì³»Àå ¼ö¼ú Àåºñ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ º¯È­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤À» ³»¸®°í, Àü·«ÀûÀÎ ÀÇ»ç°áÁ¤À» Á¤±³È­Çϸç, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¿ªÀû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Àúħ½À ¼ö¼ú Àåºñ¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡
    • ¼¼°è ³ëÀÎ Àα¸ Áõ°¡
    • ³ì³»Àå Á¶±â¹ß°ß¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÃÖ¼Òħ½ÀÀû ¼ö¼ú ÀåºñÀÇ Ã¤ÅÃÀÌ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù.
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Àúħ½À ³ì³»Àå ¼ö¼ú ÀåºñÀÇ ³ôÀº ºñ¿ë
  • ½ÃÀå ±âȸ
    • Çõ½ÅÀûÀ̰í È¿°úÀûÀÎ ³ì³»Àå ¼ö¼ú ÀåºñÀÇ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡
    • ¿ø°ÝÀÇ·á ¹× ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µÀÇ ¹ßÀü
  • ½ÃÀå °úÁ¦
    • »õ·Î¿î ³ì³»Àå ¼ö¼ú Àåºñ µµÀÔ¿¡ ´ëÇÑ ±ÔÁ¦ À庮°ú ±ä ½ÂÀÎ °úÁ¤

Portre's Five Forces: Àúħ½À ³ì³»Àå ¼ö¼ú Àåºñ ½ÃÀå °ø·«À» À§ÇÑ Àü·« Åø

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : Àúħ½À ³ì³»Àå ¼ö¼ú Àåºñ ½ÃÀåÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÃÖ¼Òħ½À ³ì³»Àå ¼ö¼ú Àåºñ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® Àúħ½À ³ì³»Àå ¼ö¼ú Àåºñ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

Àúħ½À ³ì³»Àå ¼ö¼ú Àåºñ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¸ÅÃâ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÀλçÀÌÆ®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ÃÖ¼Òħ½À ³ì³»Àå ¼ö¼ú Àåºñ ½ÃÀå¿¡¼­ÀÇ º¥´õ ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÃÖ¼Òħ½À ³ì³»Àå ¼ö¼ú Àåºñ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ ÅøÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·«Àû¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·«Àû¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àúħ½À ³ì³»Àå ¼ö¼ú Àåºñ ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× ±ÇÀå »çÇ×

Àúħ½À ³ì³»Àå ¼ö¼ú Àåºñ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº °æÀï ȯ°æÀÇ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ ü°è¸¦ ±¸ÃàÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù. :

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸°³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù. :

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÔ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå Àúħ½À ³ì³»Àå ¼ö¼ú ±â±â ½ÃÀå : µð¹ÙÀ̽ºº°

  • ¸¶ÀÌÅ©·Î½ºÅÙÆ®
  • Suprachoroidal Devices
  • Trabecular Meshwork Devices
  • Viscocanalostomy Devices

Á¦7Àå Àúħ½À ³ì³»Àå ¼ö¼ú ±â±â ½ÃÀå : ÀûÀÀÁõº°

  • Æó¼â°¢ ³ì³»Àå
  • °³¹æ°¢ ³ì³»Àå

Á¦8Àå Àúħ½À ³ì³»Àå ¼ö¼ú ±â±â ½ÃÀå : ¼ö¼úº°

  • Ab Externo
  • Ab Interno

Á¦9Àå Àúħ½À ³ì³»Àå ¼ö¼ú ±â±â ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • º´¿ø
  • ¾È°ú Ŭ¸®´Ð

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ Àúħ½À ³ì³»Àå ¼ö¼ú ±â±â ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Àúħ½À ³ì³»Àå ¼ö¼ú ±â±â ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Àúħ½À ³ì³»Àå ¼ö¼ú ±â±â ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼® 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • Abbott Medical Optics, Inc.
  • Alcon Inc.
  • Allergan PLC
  • Bausch & Lomb Inc.
  • Carl-Zeiss AG
  • Corza Ophthalmology
  • Ellex Medical Lasers Ltd.
  • Glaukos Corporation
  • InnFocus Inc.
  • IOPtima
  • iSTAR Medical
  • Ivantis, Inc.
  • Lumenis Be Ltd.
  • Neomedix Corporation
  • New World Medical, Inc.
  • Optonol Ltd.
  • Santen Pharmaceutical Co., Ltd.
  • Sight Sciences, Inc.
  • Topcon Corporation
KSA 24.12.03

The Minimally Invasive Glaucoma Surgery Devices Market was valued at USD 501.35 million in 2023, expected to reach USD 526.62 million in 2024, and is projected to grow at a CAGR of 5.35%, to USD 722.55 million by 2030.

Minimally Invasive Glaucoma Surgery (MIGS) devices are designed to reduce intraocular pressure and are primarily used in patients with mild-to-moderate glaucoma. Their less invasive nature compared to traditional surgical methods makes them a pivotal development in ophthalmic surgery. The scope of MIGS devices encompasses their necessity due to the aging global population, the increasing prevalence of glaucoma, and the demand for safer alternative treatments. These devices are applicable in various forms, including stents and shunts, which are regularly used by ophthalmologists in both standalone procedures and in conjunction with cataract surgery. End-use scope includes clinics, hospitals, and ambulatory surgical centers, with hospitals currently dominating due to the availability of skilled professionals and advanced facilities.

KEY MARKET STATISTICS
Base Year [2023] USD 501.35 million
Estimated Year [2024] USD 526.62 million
Forecast Year [2030] USD 722.55 million
CAGR (%) 5.35%

The key growth drivers of the MIGS market include the rising incidence of age-related eye disorders and increasing awareness regarding glaucoma. Additionally, the growing preference for outpatient surgical procedures boosts market expansion. Opportunities lie in developing advanced, yet more cost-effective devices to increase accessibility and adoption in developing regions. Companies are recommended to invest in research and partnerships focused on technology upgrades and exploring new surgical techniques. However, the market faces limitations due to the high cost of MIGS devices, potential complications post-surgery, and a limited number of skilled professionals.

Challenges like stringent regulatory requirements and lack of reimbursement policies in certain regions could impede market growth. To foster innovation, businesses should focus on the development of next-generation biocompatible materials and enhancing device user-friendliness, which could further broaden their application range. Research into patient-specific treatment options and personalized care models represents a valuable frontier for business growth. The MIGS market is characterized by moderate competition, with key players focused on R&D to maintain competitive advantages and the entry of new companies bringing innovative solutions expected to invigorate the sector further.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Minimally Invasive Glaucoma Surgery Devices Market

The Minimally Invasive Glaucoma Surgery Devices Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in the preference for minimally invasive surgery devices
    • Rising geriatric population globally
    • Growing awareness about early glaucoma detection promoting the adoption of minimally invasive surgical devices
  • Market Restraints
    • High costs of minimally invasive glaucoma surgery devices
  • Market Opportunities
    • Increasing investment in research and development for innovative and effective glaucoma surgery devices
    • Advancements in telemedicine and remote patient monitoring
  • Market Challenges
    • Regulatory hurdles and long approval processes for introducing new glaucoma surgery devices

Porter's Five Forces: A Strategic Tool for Navigating the Minimally Invasive Glaucoma Surgery Devices Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Minimally Invasive Glaucoma Surgery Devices Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Minimally Invasive Glaucoma Surgery Devices Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Minimally Invasive Glaucoma Surgery Devices Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Minimally Invasive Glaucoma Surgery Devices Market

A detailed market share analysis in the Minimally Invasive Glaucoma Surgery Devices Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Minimally Invasive Glaucoma Surgery Devices Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Minimally Invasive Glaucoma Surgery Devices Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Minimally Invasive Glaucoma Surgery Devices Market

A strategic analysis of the Minimally Invasive Glaucoma Surgery Devices Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Minimally Invasive Glaucoma Surgery Devices Market, highlighting leading vendors and their innovative profiles. These include Abbott Medical Optics, Inc., Alcon Inc., Allergan PLC, Bausch & Lomb Inc., Carl-Zeiss AG, Corza Ophthalmology, Ellex Medical Lasers Ltd., Glaukos Corporation, InnFocus Inc., IOPtima, iSTAR Medical, Ivantis, Inc., Lumenis Be Ltd., Neomedix Corporation, New World Medical, Inc., Optonol Ltd., Santen Pharmaceutical Co., Ltd., Sight Sciences, Inc., and Topcon Corporation.

Market Segmentation & Coverage

This research report categorizes the Minimally Invasive Glaucoma Surgery Devices Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Device, market is studied across Micro-Stents, Suprachoroidal Devices, Trabecular Meshwork Devices, and Viscocanalostomy Devices.
  • Based on Indication, market is studied across Closed-Angle Glaucoma and Open-Angle Glaucoma.
  • Based on Surgery, market is studied across Ab Externo and Ab Interno.
  • Based on End-User, market is studied across Ambulatory Surgical Center, Hospital, and Ophthalmology Clinic.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in the preference for minimally invasive surgery devices
      • 5.1.1.2. Rising geriatric population globally
      • 5.1.1.3. Growing awareness about early glaucoma detection promoting the adoption of minimally invasive surgical devices
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of minimally invasive glaucoma surgery devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investment in research and development for innovative and effective glaucoma surgery devices
      • 5.1.3.2. Advancements in telemedicine and remote patient monitoring
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory hurdles and long approval processes for introducing new glaucoma surgery devices
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Device : Increasing preference for micro-stents for patients in the early-to-moderate stages of glaucoma
    • 5.2.2. End-user : Growing demand for minimally invasive glaucoma surgery (MIGS) devices in hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Minimally Invasive Glaucoma Surgery Devices Market, by Device

  • 6.1. Introduction
  • 6.2. Micro-Stents
  • 6.3. Suprachoroidal Devices
  • 6.4. Trabecular Meshwork Devices
  • 6.5. Viscocanalostomy Devices

7. Minimally Invasive Glaucoma Surgery Devices Market, by Indication

  • 7.1. Introduction
  • 7.2. Closed-Angle Glaucoma
  • 7.3. Open-Angle Glaucoma

8. Minimally Invasive Glaucoma Surgery Devices Market, by Surgery

  • 8.1. Introduction
  • 8.2. Ab Externo
  • 8.3. Ab Interno

9. Minimally Invasive Glaucoma Surgery Devices Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Center
  • 9.3. Hospital
  • 9.4. Ophthalmology Clinic

10. Americas Minimally Invasive Glaucoma Surgery Devices Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Minimally Invasive Glaucoma Surgery Devices Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Minimally Invasive Glaucoma Surgery Devices Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. New World Medical Secures 510(k) Clearance for Expanded Kahook Dual Blade, Enhancing Glaucoma Treatment Options and Market Reach
    • 13.3.2. OMNI Surgical System by Sight Sciences Shows Promising Results in Glaucoma Treatment, Anticipating Wider Adoption and Market Growth
    • 13.3.3. iSTAR Medical SA Achieves CE Mark for Glaucoma Device, Eyes Expansion into U.S. Market
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Medical Optics, Inc.
  • 2. Alcon Inc.
  • 3. Allergan PLC
  • 4. Bausch & Lomb Inc.
  • 5. Carl-Zeiss AG
  • 6. Corza Ophthalmology
  • 7. Ellex Medical Lasers Ltd.
  • 8. Glaukos Corporation
  • 9. InnFocus Inc.
  • 10. IOPtima
  • 11. iSTAR Medical
  • 12. Ivantis, Inc.
  • 13. Lumenis Be Ltd.
  • 14. Neomedix Corporation
  • 15. New World Medical, Inc.
  • 16. Optonol Ltd.
  • 17. Santen Pharmaceutical Co., Ltd.
  • 18. Sight Sciences, Inc.
  • 19. Topcon Corporation
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦